Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index; 17 of the 34 sources its claims cite were checked for support.
Abstract
BACKGROUND: Obstructive sleep apnea is characterized by disordered breathing during sleep and is associated with major cardiovascular complications; excess adiposity is an etiologic risk factor. Tirzepatide may be a potential treatment. METHODS: We conducted two phase 3, double-blind, randomized, controlled trials involving adults with moderate-to-severe obstructive sleep apnea and obesity. Participants who were not receiving treatment with positive airway pressure (PAP) at baseline were enrolled in trial 1, and those who were receiving PAP therapy at baseline were enrolled in trial 2. The participants were assigned in a 1:1 ratio to receive either the maximum tolerated dose of tirzepatide (10 mg or 15 mg) or placebo for 52 weeks. The primary end point was the change in the apnea-hypopnea index (AHI, the number of apneas and hypopneas during an hour of sleep) from baseline. Key multiplicity-controlled secondary end points included the percent change in AHI and body weight and changes in hypoxic burden, patient-reported sleep impairment and disturbance, high-sensitivity C-reactive protein (hsCRP) concentration, and systolic blood pressure. RESULTS: At baseline, the mean AHI was 51.5 events per hour in trial 1 and 49.5 events per hour in trial 2, and the mean body-mass index (BMI, the weight in kilograms divided by the square of the height in meters) was 39.1 and 38.7, respectively. In trial 1, the mean change in AHI at week 52 was -25.3 events per hour (95% confidence interval [CI], -29.3 to -21.2) with tirzepatide and -5.3 events per hour (95% CI, -9.4 to -1.1) with placebo, for an estimated treatment difference of -20.0 events per hour (95% CI, -25.8 to -14.2) (P<0.001). In trial 2, the mean change in AHI at week 52 was -29.3 events per hour (95% CI, -33.2 to -25.4) with tirzepatide and -5.5 events per hour (95% CI, -9.9 to -1.2) with placebo, for an estimated treatment difference of -23.8 events per hour (95% CI, -29.6 to -17.9) (P<0.001). Significant improvements in the measurements for all prespecified key secondary end points were observed with tirzepatide as compared with placebo. The most frequently reported adverse events with tirzepatide were gastrointestinal in nature and mostly mild to moderate in severity. CONCLUSIONS: Among persons with moderate-to-severe obstructive sleep apnea and obesity, tirzepatide reduced the AHI, body weight, hypoxic burden, hsCRP concentration, and systolic blood pressure and improved sleep-related patient-reported outcomes. (Funded by Eli Lilly; SURMOUNT-OSA ClinicalTrials.gov number, NCT05412004.).
Overview
CoChat Summary
## TL;DR
In two 52-week phase 3 randomized controlled trials of adults with moderate-to-severe obstructive sleep apnea and obesity, tirzepatide improved apnea-hypopnea index (AHI) and multiple secondary outcomes versus placebo. The paper concludes that tirzepatide reduced sleep-disordered breathing, body weight, hypoxic burden, hsCRP, systolic blood pressure, and improved sleep-related patient-reported outcomes.
## Key findings
- In trial 1, the mean change in AHI at week 52 was -25.3 events/hour with tirzepatide versus -5.3 events/hour with placebo; the estimated treatment difference was -20.0 events/hour (95% CI, -25.8 to -14.2; P<0.001).
- In trial 2, the mean change in AHI at week 52 was -29.3 events/hour with tirzepatide versus -5.5 events/hour with placebo; the estimated treatment difference was -23.8 events/hour (95% CI, -29.6 to -17.9; P<0.001).
- In the pooled analysis, participants receiving tirzepatide had significant reductions in PROMIS-SRI and PROMIS-SD T scores, and both trials showed significant reductions in body weight, systolic blood pressure, and hsCRP concentrations.
- The paper states that the most frequently reported adverse events with tirzepatide were gastrointestinal and generally mild-to-moderate; adverse events occurred in 79.8% vs 76.7% of participants in trial 1 and 83.2% vs 72.8% in trial 2 (tirzepatide vs placebo).
## Methods
- Two 52-week, phase 3, multicenter, parallel-group, double-blind, randomized, controlled trials were conducted at 60 sites across nine countries.
- Adults with moderate-to-severe obstructive sleep apnea (AHI ≥15 events/hour) and obesity (BMI ≥30; ≥27 in Japan) were enrolled; trial 1 included participants unable or unwilling to use PAP, and trial 2 included participants using PAP for at least 3 consecutive months and planning to continue.
- Participants were randomized 1:1 to weekly tirzepatide (10 mg or 15 mg maximum tolerated dose) or placebo; the primary endpoint was change in AHI from baseline, with key secondary endpoints including AHI percent change, body weight, hypoxic burden, hsCRP, patient-reported sleep outcomes, and systolic blood pressure. Analyses used ANCOVA and logistic regression, with multiplicity control via a graphical testing procedure.
## Limitations
- The paper states that the shorter duration of the trials does not support assessment of long-term cardiovascular outcomes.
- The trials excluded participants without obesity and did not assess people with overweight or normal BMI.
- The trials were not designed to test whether results differed by baseline symptoms, and trial 2 was not designed to assess PAP adherence effects; also, the minimum clinically important changes for PROMIS-SRI and PROMIS-SD were not established.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
14 Valid · 0 Not valid · 6 Not checked · 57 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Excess adiposity is a major reversible etiologic risk factor for obstructive sleep apnea and its complications. 8,9”
What the sources say
- Supportedcites [8] 8. Hudgel DW, Patel SR, Ahasic AM, et al. The role of weight management in the treatment of adult obstructive sleep apnea: an official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med 2018;198(6):e70-e87. [PubMed: 30215551] source
The Introduction says weight gain is linked to the development and worsening of OSA and that obesity aggravates its metabolic and cardiovascular comorbidities. “Putting It All Together” reports that weight loss consistently improves OSA severity and may improve associated health outcomes, supporting reversibility. (LLM, conf=0.90)
- Not checked — no full text of the sourcecites [9] 9. Morgenthaler TI, Kapen S, Lee-Chiong T, et al. Practice parameters for the medical therapy of obstructive sleep apnea. Sleep 2006;29:1031-5. [PubMed: 16944671] source
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“This level of weight reduction has been difficult to accomplish with lifestyle intervention alone. 35”
What the sources say
- Partly supportedcites [35] 35. Dombrowski SU, Knittle K, Avenell A, Araújo-Soares V, Sniehotta FF. Long term maintenance of weight loss with non-surgical interventions in obese adults: systematic review and meta-analyses of randomised controlled trials. BMJ 2014;348:g2646. [PubMed: 25134100] sourceExperimental — accuracy not yet measured
The Introduction says few people maintain weight loss over the long term, and the Behavioural/lifestyle v control section reports a modest mean difference of −1.56 kg at 12 months. This supports the general difficulty of sustaining weight loss with lifestyle intervention, but the claim does not specify what “this level” is, so the paper cannot verify that particular level. (LLM, conf=0.78)
- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The potential issue of PAP confounding of the PROMIS outcomes in trial 2 was minimized by a 7-day PAP washout period. 22”
What the sources say
- Partly supportedcites [22] 22. Schwarz EI, Stradling JR, Kohler M. Physiological consequences of CPAP therapy withdrawal in patients with obstructive sleep apnoea-an opportunity for an efficient experimental model. J Thorac Dis 2018;10:Suppl 1:S24-S32. [PubMed: 29445525] sourceExperimental — accuracy not yet measured
The Physiological effects of CPAP withdrawal section reports that OSA recurred and subjective sleepiness increased one week after CPAP withdrawal, supporting the rationale for a washout. It does not assess PROMIS outcomes or establish that seven days minimized PAP confounding in trial 2; sleepiness continued to increase at two weeks. (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The safety profile of tirzepatide was consistent with that observed in previous trials. 14,3739”
What the sources say
- Not checked — no full text of the sourcecites [14] 14. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med 2022;387:205-16. [PubMed: 35658024] source
- Supportedcites [37] 37. Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebocontrolled, phase 3 trial. Lancet 2023;402:613-26. [PubMed: 37385275] source
The Discussion explicitly states that tirzepatide’s safety profile was consistent with previous findings in the SURMOUNT-1 and SURPASS trials. The Safety section also describes the adverse events observed in this trial. (LLM, conf=0.95)
- Supportedcites [38] 38. Wadden TA, Chao AM, Machineni S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nat Med 2023;29:2909-18. [PubMed: 37840095] source
The Discussion explicitly states that tirzepatide’s safety profile in this trial was consistent with findings from previous tirzepatide trials. It also notes modestly higher rates of gastrointestinal adverse events and treatment discontinuation than in the tirzepatide 15 mg group in SURMOUNT-1; that qualification does not negate the overall comparison. (LLM, conf=0.95)
- Partly supportedcites [39] 39. Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA 2024;331:38-48. [PubMed: 38078870] sourceExperimental — accuracy not yet measured
The Results (Adverse Events and Tolerability; page unavailable) describe tirzepatide’s safety findings, including gastrointestinal events and serious adverse events. The passages do not compare that safety profile with previous trials, so the claimed consistency with earlier findings is not established by our copy. (LLM, conf=0.82)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There were five cases of severe or serious depressive disorder or suicidal ideation or behavior events across both trials (two with tirzepatide and three with placebo).”
plainn = 5- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
29 more claims
Create a free account to see all 77 claims and every source verdict.
- Probably not a substantial claim. 29
- It may state two separate claims as one. 31
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“However, some studies were designed for other purposes17,18,30,41–44—for example, prevention of CVD or T2D.”
From A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults (2025) · cites this paper as [43]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These medications allow most patients to achieve clinically meaningful weight loss, improve severity of OSA, and improve cardiometabolic comorbidities.13,14”
From Receipt of Glucagon-Like Peptide-1 Receptor Agonists Among Rural Patients with Obstructive Sleep Apnea and Excess Weight (2026) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These medications allow most patients to achieve clinically meaningful weight loss, improve severity of OSA, and improve cardiometabolic comorbidities.13,14”
From Receipt of Glucagon-Like Peptide-1 Receptor Agonists Among Rural Patients with Obstructive Sleep Apnea and Excess Weight (2026) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These medications allow most patients to achieve clinically meaningful weight loss, improve severity of OSA, and improve cardiometabolic comorbidities.13,14”
From Receipt of Glucagon-Like Peptide-1 Receptor Agonists Among Rural Patients with Obstructive Sleep Apnea and Excess Weight (2026) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SURMOUNT-OSA trial reported that tirzepatide reduced the apnea-hypopnea index by 25% to 29% over 52 weeks in individuals with obesity and moderate to severe OSA, compared with a reduction of 5.3% to 5.5% in the placebo group, regardless of the use of positive airway pressure therapy (19).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [19]
Experimental — accuracy not yet measured
16 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Benjafield, A. V., Ayas, N. T., Eastwood, P. R., Heinzer, R., Ip, M. S. M., Morrell, M. J., Nunez, C. M., Patel, S. R., Penzel, T., Pépin, J.-L., et al. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30198-5 · Cited by 4,326
Self-citationTirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Self-citationAdult Obstructive Sleep Apnea Task Force of the American Academy of Sleep Medicine, Epstein, L. J., Kristo, D., Strollo, P. J., Friedman, N., Malhotra, A., Patil, S. P., Ramar, K., Rogers, R., Schwab, R. J., et al. (2009) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.27497 · Cited by 3,360
Self-citationCPAP for Prevention of Cardiovascular Events in Obstructive Sleep Apnea
McEvoy, R. D., Antic, N. A., Heeley, E., Luo, Y., Ou, Q., Zhang, X., Mediano, O., Chen, R., Drager, L. F., Liu, Z., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606599 · Cited by 2,101
Self-citationGarvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Adult obstructive sleep apnoea
Jordan, A. S., McSharry, D. G., & Malhotra, A. (2014) · The Lancet · doi:10.1016/s0140-6736(13)60734-5 · Cited by 1,735
Self-citationJavaheri, S., Barbe, F., Campos-Rodriguez, F., Dempsey, J. A., Khayat, R., Javaheri, S., Malhotra, A., Martinez-Garcia, M. A., Mehra, R., Pack, A. I., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.11.069 · Cited by 1,434
Self-citationYeghiazarians, Y., Jneid, H., Tietjens, J. R., Redline, S., Brown, D. L., El-Sherif, N., Mehra, R., Bozkurt, B., Ndumele, C. E., Somers, V. K., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000988 · Cited by 1,431
Self-citationRamar, K., Dort, L. C., Katz, S. G., Lettieri, C. J., Harrod, C. G., Thomas, S. M., & Chervin, R. D. (2015) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.4858 · Cited by 915
Azarbarzin, A., Sands, S. A., Stone, K. L., Taranto-Montemurro, L., Messineo, L., Terrill, P. I., Ancoli-Israel, S., Ensrud, K., Purcell, S., White, D. P., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehy624 · Cited by 893
Self-citation
Cited by
Items 501–600 of 823
Beyond efficacy: the treatment lifecycle of incretin and multi-receptor agonists
Rabbani, S. A., El-Tanani, M., Matalka, I. I., & Rizzo, M. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1902185
Pharmacotherapy for Obstructive Sleep Apnea: From Pathophysiology to Emerging Treatments
Zhou, R., Yin, G., Zhu, Y., & Sun, Y. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15166473
Canecki-Varžić, S., Bilić-Čurčić, I., Bakula, M., Bulum, T., Naglić, M. Č., Delić-Brkljačić, D., Wensveen, T. T., Vitković, D. F., Jurišić‐Eržen, D., Klobučar, S., et al. (2026) · Frontiers in Aging · doi:10.3389/fragi.2026.1834323 · Cited by 1
Gracioto, P. G. A., de Oliveira, J. C. M., & Oliveira, C. R. (2026) · Research Society and Development · doi:10.33448/rsd-v15i7.51444
Positional Obstructive Sleep Apnea: A Model for Precision Sleep Medicine
Prabakar, A., Eskandari, S., Murudkar, T., Song, W., Liu, X., Kwon, Y., & Healy, W. J. (2026) · Journal of Otorhinolaryngology Hearing and Balance Medicine · doi:10.3390/ohbm7020023
Obesity in pediatric sleep medicine evaluations: insights from a real-world multicenter analysis
Landeo‐Gutierrez, J., Bedoya, M., MacKintosh, E. W., Ryu, J., Bhattacharjee, R., & Chen, M. L. (2026) · Journal of Clinical Sleep Medicine · doi:10.1007/s44470-026-00138-z
A consensus statement from the European Society for Clinical Investigation
Carbone, F., Després, J., Ioannidis, J. P. A., Neeland, I. J., Garruti, G., Busetto, L., Liberale, L., Ministrini, S., Vilahur, G., Schindler, T. H., et al. (2025) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
ROLE OF SLEEP DISORDERS IN TYPE 2 DIABETES MELLITUS - A REVIEW OF CURRENT LITERATURE
Bogdan-Groszyk, Z., Mikula, L., Otrębska, K., Lewandowska, D., Makulec, A., Jóźwik-Szymańska, A., Kostecka, N., Szredzka, A., & Kucharski, J. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(51).2026.6666
Kaufmann, C. N., Yang, K. H., Tseng, C., Chang, G., Amjad, H., Albrecht, J., Spira, A. P., Gross, A. L., Wickwire, E. M., & Malhotra, A. (2026) · The Journals of Gerontology Series A · doi:10.1093/gerona/glag078
Self-citationExpert consensus on osteoporosis risk management in patients with sleep disorders
Leng, S., Yang, J., Jin, Y., Shi, J., Zhang, Y., Zhou, J., Tan, L., Li, T., Ni, P., Hu, K., et al. (2026) · Bone Research · doi:10.1038/s41413-026-00562-0
Maximizing Obesity Therapy: Strategic Use of Anti-obesity Pharmacotherapy
Bartfield, J. K., & Bonnecaze, A. K. (2026) · Springer eBooks · doi:10.1007/978-3-032-24278-5_70
Predictors of Decision to Pursue Sleep Surgery
Husman, T., Bhat, A., Durr, M. L., & Chang, J. L. (2025) · OTO Open · doi:10.1002/oto2.70093
Dugan, L., Naqvi, A., Ngor, A., Totlani, J., Chang, T. Y., Hirsch, D., Abdelmoteleb, S., Parrish, T., Nayyar, P. P., Truman, K. A., et al. (2025) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000002049
Vilarrasa, N., & Pellitero, S. (2025) · Medicina Clínica · doi:10.1016/j.medcli.2025.107184 · Cited by 2
Sattar, N. A., Mamas, M. A., Li, R., García‐Pérez, L., Chen, K. L., Upadhyay, N., Glass, L., Batterham, R. L., Dimitriadis, G. K., & Liu‐Seifert, H. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag408
Obstructive Sleep Apnea in Women
Khullar, A., & Swainson, J. (2024) · Canadian Women s Health Today · doi:10.58931/cwht.2024.1316
Li, J.-K., Wang, R., Meng, X.-Y., & Kang, J. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02890-3
Autonomic nervous system: an integrative regulator in circadian rhythm of blood pressure
Yu, Z., Zhao, M., Xu, H., Sun, J., & Jin, X. (2026) · Frontiers in Neurology · doi:10.3389/fneur.2026.1766490
Ahmed, M. (2025) · Journal of Prevention Diagnosis and Management of Human Diseases · doi:10.55529/jpdmhd.52.68.79
Obstruktive Schlafapnoe und Inflammation
Schulz, R., & Schulz, E. (2025) · Somnologie - Schlafforschung und Schlafmedizin · doi:10.1007/s11818-025-00493-8
Obesity in Living Kidney Donors from Risk to Ethics: Bridging Gaps in Evaluation and Management
Budhiraja, P., Bzoma, B., Đenić, A., Issa, N. S., McKee, K., Schinstock, C., Taler, S. J., Chakkera, H. A., Heimbach, J. K., Jadlowiec, C. C., et al. (2026) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000001030 · Cited by 2
Papastathopoulou, N. S., Neri, S., Assirelli, E., D’Amuri, A., Greco, S., Ciaffi, J., & Ursini, F. (2026) · Rheumatology Advances in Practice · doi:10.1093/rap/rkag105
Effect of tirzepatide and semaglutide on blood pressure: A systematic review and meta-analysis
Chen, Q.-X., Xiao-yu, Z., Wu, Q., Xie, J.-J., Xu, Y., Teng, F., & Guo, M. (2026) · Endocrine · doi:10.1007/s12020-026-04757-7
Kim, H. S. J., Tran, T. H., Schmickl, C. N., & Slejko, J. F. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70938
Silva, D., Baur, L. A., & Fitzgerald, D. A. (2025) · Paediatric Respiratory Reviews · doi:10.1016/j.prrv.2025.08.001 · Cited by 1
Pulmonary hypertension related to sleep-disordered breathing
LACAVERA, M., Asghar, A., Ballard, J., Bandla, M., & Fraidenburg, D. R. (2026) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000001307
You, S., Zheng, D., Loffler, K. A., McEvoy, R. D., Li, Q., Han, Q., Barbé, F., Liu, C., Cao, Y., Wang, X., et al. (2026) · Neurology · doi:10.1212/wnl.0000000000218334 · Cited by 1
Pharmacotherapy of Obstructive Sleep Apnea in Adults
Huang, Y., Chin, W., & Wang, T. (2025) · Springer eBooks · doi:10.1007/978-981-95-2648-2_7
Melanocortin 4 receptor signalling in sleep‐disordered breathing
Islam, M. T., Amorim, M. R., & Polotsky, V. Y. (2026) · The Journal of Physiology · doi:10.1113/jp290177
Tanrıverdi, U., & Senel, G. B. (2026) · Current Treatment Options in Neurology · doi:10.1007/s11940-026-00890-w
Anttalainen, U., Lammintausta, A., & Saaresranta, T. (2026) · Current Pulmonology Reports · doi:10.1007/s13665-026-00409-3 · Cited by 1
Mutchmore, A., Cauchon, M., Plourde, M.-É., & Lanthier, L. (2024) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2024.12.002
iCARDIO Alliance Global Implementation Guidelines for the Management of Obesity 2025
Anker, S. D., Ji, L., Kindel, T. L., Coats, A. J. S., Ojji, D. B., Puente-Barragán, A., Rossing, P., Zieroth, S. R., Ahmad, S., Usman, S., et al. (2026) · International Journal of Cardiovascular Sciences · doi:10.36660/ijcs.20260056
李, 晓. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.1693223
Mind the sleep: how does obstructive sleep apnoea syndrome relate to risk of dementia?
Lisik, D., & Zou, D. (2025) · Thorax · doi:10.1136/thorax-2024-222873
Obstructive Sleep Apnea in Stroke Rehabilitation: A Physical Medicine and Rehabilitation Perspective
Abdulsalam, A. J., Al-Hashel, J. Y., Abdulsalam, M., & Özçakar, L. (2026) · American Journal of Physical Medicine & Rehabilitation · doi:10.1097/phm.0000000000003040
Mendonca, C. A., Rathi, K. K., Williams, A.-L., Attre, A., Salmon, A., Mortensen, E. M., & Maheshwari, N. (2026) · Sleep Medicine · doi:10.1016/j.sleep.2026.109042
Ahmed, A., Segal, S., & Gibber, M. J. (2026) · Sleep And Breathing · doi:10.1007/s11325-026-03736-6
Harnessing the gut-brain axis in the treatment of type 2 diabetes mellitus and obesity
Kotucha, K., Kapłon, K., Moś, M., Fiegler-Rudol, J., Pietryszyn-Bilińska, A., Dynarowicz, K., Aebisher, D., Wiench, R., & Kawczyk‐Krupka, A. (2025) · European Journal of Clinical and Experimental Medicine · doi:10.15584/ejcem.2025.4.24
Wong, S., Baek, J., Zhang, M. C., Fabiano, N., Zhou, C., Lee, E. K., Solmi, M., Husain, M. I., & Mak, M. S. B. (2026) · Psychiatry International · doi:10.3390/psychiatryint7040170
Exploring the therapeutic potential of GLP-1 receptor agonists in pulmonary arterial hypertension
Aguado, B., Lacoste-Palasset, T., Ruffenach, G., Bauer, F., Savale, L., Humbert, M. J. C., Montani, D., & Antigny, F. (2025) · ERJ Open Research · doi:10.1183/23120541.01479-2025
Merolla, A., & Rovere, P. Q. (2026) · Cardiac failure review · doi:10.15420/cfr.2026.22
Balasan, N., Zorzi, M., Ura, B., Robino, A., Dalena, P., Addobbati, R., Stazio, M. D., Zago, A., D’Adamo, P., Grasso, D. L., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27177658
Faut-il faire maigrir les patients ayant une insuffisance respiratoire chronique et une obésité ?
Borel, A., Suzeau, P., & Borel, J. (2025) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2025.06.004
Weight loss for obstructive sleep apnoea: first-line therapy should not mean single-line therapy
Yin, Z., & Wei, L. (2026) · European Respiratory Review · doi:10.1183/16000617.0169-2026
Antiobesity Medications and Endoscopic Bariatric Therapies: A Narrative Review
Frankl, L., Kim, L. N., & Popov, V. (2026) · Techniques and Innovations in Gastrointestinal Endoscopy · doi:10.1016/j.tige.2026.250976
Diagnostic et traitement du syndrome d’apnées-hypopnées obstructives du sommeil de l’adulte
Bironneau, V., & Meurice, J. C. (2025) · Encyclopédie médico-chirurgicale. Pneumologie · doi:10.1016/s1155-195x(25)45857-5
Kachmar, M., Wall‐Wieler, E., Liu, Y., Zheng, F., Singh, P., & Albaugh, V. L. (2025) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2025.01.009 · Cited by 1
From adiposity to multisystem morbidity: the case for weight loss as disease modification
Sattar, N. A., Ferguson, L. D., & Lee, M. M. Y. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00186-5
Obstructive sleep apnea pharmacology
Sunwoo, B. Y., Schmickl, C. N., & Malhotra, A. (2026) · Canadian Journal of Respiratory Critical Care and Sleep Medicine · doi:10.1080/24745332.2026.2695024
Self-citationKuryłowicz, A., & Czupryniak, L. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71226 · Cited by 3
Glp-1 receptor agonists in obesity: Current evidence and clinical outcomes
Vidal, J. (2026) · Advances in pharmacology · doi:10.1016/bs.apha.2026.08.009
Alam, A. (2026) · Bangladesh Journal of Endocrinology and Metabolism · doi:10.4103/bjem.bjem_17_26
Does glucose metabolism and its consequences depend on the phenotype of obstructive sleep apnea?
Suwannakin, A., Reutrakul, S., & Chirakalwasan, N. (2025) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000001206
Letter response to Van Bruggen: Obesity, sleep apnea and incretin therapy
Malhotra, A., & Bednařík, J. (2025) · Sleep Medicine · doi:10.1016/j.sleep.2025.108651
Self-citationVastrad, B. M., & Vastrad, C. M. (2025) · Research Square · doi:10.21203/rs.3.rs-8076420/v1
Leonhard, A. G., Coggeshall, S. S., Gleason, E., Collins, M. P., Barjaktarević, I., Bascom, R., Bon, J. M., Comellas, A. P., Diaz, P. T., Hanania, N. A., et al. (2025) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202504-410oc
González-Cuello, C. L., Bosco, G., Navarro-Mediano, R. A., Molina, M. G. C., Scarcella, A., & Plaza‐Mayor, G. (2025) · Revista ORL · doi:10.14201/orl.33510
Uncertainty-Aware Upper Airway Segmentation for Non-Obese OSA
Wu, M., Lu, R., Lin, C., et al. (2026) · doi:10.1109/ust70584.2026.11663988
Economic evaluations of antiobesity medications: A systematic literature review
Jurković, M., Fajkić, A., Faour, A. K., Momčilović, M., Turčić, P., & Belančić, A. (2026) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70825
Chun Kwan, O., Chan, R. N., Chan, K. P., Wu, H., Lam, F. M., Lee, H. H., Chow, E., Luk, A. O. Y., Ronald, C. W., Wing, Y. K., et al. (2025) · Primary care diabetes · doi:10.1016/j.pcd.2025.12.003
Ren, M., Guihua, S. O. N. G., Zhang, B., Sun, M., Yu, S., & Zhang, Y. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1894904
Król, M., Woźniak, A., Straszewska, A., Sobantka, P., Mokrzecki, S., Mamach, A., Aleksandrowicz, K., Grodzka, Z., Meszka, M., Bełc, E., et al. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.2(50).2026.6208
Obstruktive Schlafapnoe: Auswirkungen auf den Glukosestoffwechsel
Schöbel, C. (2025) · CME · doi:10.1007/s11298-026-4572-9
Allaham, L., King, B. J., Ali, F., GUPTA, I., Metuku, R., Nieto, I., Lurie, A., Amer, F. N., Reddy, R., & Alzghoul, B. N. (2026) · Lung · doi:10.1007/s00408-026-00939-2
Afloarei, C. A., Antal, A. Z., Toma, D. D., Pintilie, A.-L., Pitusac, G., Tiron, R., Bîrladeanu, T., Zaharia, T., & Crișan-Dabija, R. A. (2026) · Advances in respiratory medicine · doi:10.3390/arm94050063
Carretero‐Gómez, J., Rodríguez, J. M. F., Doña, A. M., Miramontes‐González, J. P., Soler, J. J. G., Soto, M. I. P., Carrasco-Sánchez, F. J., Gómez-Delgado, F., Arévalo‐Lorido, J. C., & Martínez, P. P. (2025) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2025.502352 · Cited by 1
Clinical Decision-Making for Incretin-Based Therapy in Neurofibromatosis Type 1
Ayar, U. D., Akurati, S., Petridis, S. F., Mejia, H., Udayakumar, V., Punjabi, N., Bernal‐Mizrachi, E., & Varghese, R. T. (2026) · AACE Endocrinology and Diabetes · doi:10.1016/j.aed.2026.07.024
TIRZEPATIDA E OS RISCOS DO USO SEM PRESCRIÇÃO MÉDICA
Silva, B. E., Alves, N. D., Francelino, J. D. S., Spaziani, A. O., Eleutério, B. M. G., da Silva, F. S., Gonzaga, D. M. I. D. S., & Franco, R. F. (2026) · Revista de Geopolítica · doi:10.56238/revgeov17n6-005 · Cited by 1
A Review of Lifestyle Interventions Provided as an Adjunct to Obesity Management Medications
Chao, A. M., Asante, R., Sersah, M. E., Jahangir, U. A., Peary, A., & Kudaya, D. Q. (2026) · Obesity Science & Practice · doi:10.1002/osp4.70162
Molano, J. R. V. (2026) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2026.07.007
Lowering blood pressure with continuous positive airway pressure: a work in progress
Covassin, N. (2025) · European Respiratory Journal · doi:10.1183/13993003.02128-2024
Patient characteristics and early experiences with anti-obesity medications: the CAMP study
Tewksbury, C. M., Soliva, E. A., Scheffey, K., Kwong, P. L., & Glanz, K. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1931188
Les meilleures études en 2024 adaptées aux soins primaires
Moe, S. S., Perry, D., Thomas, B. S., Nickonchuk, T., Braschi, É., Dugré, N., Finley, C. R., Lindblad, A. J., Potter, J., & Allan, G. M. (2025) · Canadian Family Physician · doi:10.46747/cfp.7105e77
Obstructive Sleep Apnoea and Atrial Fibrillation: Current Evidence and Emerging Research Directions
Basiukiewicz, P., Chen, S., Mills, M. T., & Futyma, P. (2026) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm50804
Nouveaux médicaments de l’obésité : quelle pertinence ?
Bringer, J. (2025) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2025.02.008
Tirzepatide in type 1 diabetes: beyond mere weight loss
Panou, T., Gouveri, E., Popovic, D. S., & Παπάνας, Ν. (2026) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2026.2685653
Evolution of concepts on optimal nutrition as a pillar for improving metabolic health
Demidova, T. Y., Nikitin, I. G., Starodubova, A. V., Кislyak, O. A., & Izmaylova, M. Y. (2026) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2026-191
Tirzepatide in Obstructive Sleep Apnea: Targeting Obesity and Hypoxic Burden
Sarker, M. M. (2026) · Bangladesh Journal of Endocrinology and Metabolism · doi:10.4103/bjem.bjem_36_26
Wartko, P. D., Zhang, R., Johnson, E., Begle, C., Bobb, J. F., Chen, C., Singh, A., ROSS, L. C., O’Connor, P. J., Arterburn, D. E., et al. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113504
Chen, A. S., Brunetto, W. L., Canavan, M., Lipska, K. J., Richey, E. A., Wilson, M. S., Zarro, J., & Ross, J. S. (2025) · Journal of General Internal Medicine · doi:10.1007/s11606-025-09691-4 · Cited by 1
Pediatric Obesity and Obstructive Sleep Apnea
Jones, H., Tayara, A., Baldassari, C. M., & Anne, S. (2026) · Otolaryngologic Clinics of North America · doi:10.1016/j.otc.2026.06.003
Gómez-Maldonado, I., Rodríguez-Arana, A., Tamayo-Pinzón, A., Albornoz-Suárez, J. E., Lopez-Franco, M. J., Mejia-Manrique, J. A., Forero-Caycedo, J. J., Rojas-Rodríguez, L. C., Buitrago-Ricaurte, N., Gaviria-Carrillo, M., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27167108
Lin, Y. N., Sun, X. W., Dai, S. J., Zhuang, H. X., Liu, J. J., & Li, Q. Y. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2026.104203
Mansouri, E. S., de Queiroga, F. F., Barbosa, L., Azevedo, A. K., Donaldy, W., Mirbolouk, M. J., Freire, C. V. S., Rivera, A., Félix, I. F., Abreu, M., et al. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.044249 · Cited by 1
Glucagon-Like Peptide-1 Receptor Agonists for Obstructive Sleep Apnea: A Review
Harris, A., & Kaffenberger, T. M. (2026) · JAMA Otolaryngology–Head & Neck Surgery · doi:10.1001/jamaoto.2026.2266 · Cited by 1
Management kardiovaskulärer Erkrankungen bei Adipositas
Baessler, A., Zurkan, D., Bischoff, G., Esefeld, K., Hümmelgen, M., Aberle, J., Wienbergen, H., Blüher, M., Werner, N., Müller, O. J., et al. (2026) · Die Kardiologie · doi:10.1007/s12181-026-00813-8 · Cited by 1
Identifying High-Risk Obese Individuals Without Diabetes for GLP-1RA Therapy Using Coronary CTA
Blair, C. V., Huck, D. M., Besser, S. A., Cardoso, R. N., Shiyovich, A., Berman, A. N., Biery, D. W., Weber, B., Petranović, M., Nasir, K., et al. (2025) · JACC Advances · doi:10.1016/j.jacadv.2025.101995
Rapid uptake of glucagon-like peptide-1 receptor agonists among adults with obstructive sleep apnea
Lin, A., Sun, S., Kutler, R. B., et al. (2026) · SLEEP · doi:10.1093/sleep/zsag147
Metabolic Syndrome: Redefine and Expand Its Reach, Yet Preserve Its Clinical Value
Saad, M. J. A., Santos, A., Geloneze, B., & Velloso, L. A. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.07.008 · Cited by 1
Revolución metabólica: redefiniendo la endocrinología con nuevas terapias basadas en incretinas
Hernández, A. R., Araujo, J. E. G., Castillo, J. F. D., Martínez, M. E. A., Cohen, N. E. Z., Navarro, A. F. U., Chavez, M. A. N., & Morales, A. L. L. (2025) · Star of Sciences Multidisciplinary Journal · doi:10.63969/tg610p62
Fang, Q., Zhu, Y., Rao, M., & Liu, P. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1752341 · Cited by 2
Sleep apnea, heart health and testosterone: unravelling the triad of well-being
Andersen, M. L., Alvarenga, T. A., Glauser, V. A., Vasco, M. B., Drager, L. F., & Tufik, S. B. (2026) · EBioMedicine · doi:10.1016/j.ebiom.2026.106157 · Cited by 1
The Future of Obstructive Sleep Apnea Treatment: A Paradigm Shift?
Choi, J. H. (2025) · Sleep Medicine Research · doi:10.17241/smr.2025.02908
Minari, T. P., Vilela-Martin, J. F., & Pisani, L. P. (2026) · Nutrition Reviews · doi:10.1093/nutrit/nuag115
Metadata
- Authors
- Malhotra, A., Grunstein, R. R., Fietze, I., Weaver, T. E., Redline, S., Azarbarzin, A., Sands, S. A., Schwab, R. J., Dunn, J. P., Chakladar, S., Bunck, M. C., & Bednarik, J.
- Affiliations
- Brigham and Women's Hospital (US)
- From the University of California, San Diego, La Jolla (A.M.); Woolcock Institute of Medical Research, Macquarie University, Royal Prince Alfred Hospital, and the University of Sydney — all in Sydney (R.R.G.); the Center of Sleep Medicine, Charité University Hospital Berlin, Berlin (I.F.); the College of Nursing, University of Illinois Chicago, Chicago (T.E.W.); the School of Nursing (T.E.W.) and Perelman School of Medicine (R.J.S.), University of Pennsylvania, Philadelphia; the Division of Sleep and Circadian Disorders, Brigham and Women’s Hospital, and Harvard Medical School — both in Boston (S.R., A.A., S.A.S.); and Eli Lilly, Indianapolis (J.P.D., S.C., M.C.B., J.B.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-10-03
- Volume
- 391
- Issue
- 13
- Pages
- 1193-1205
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC11598664
- OpenAlex
- W4399907994
- Cited by
- 871
- References
- 39
- Citations by year
- 2026: 410 · 2025: 379 · 2024: 80
- FWCI
- 245.31
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Physiology (medical) › Obstructive Sleep Apnea Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Pharmacology (medical) › Apelin-related biomedical research
- Keywords
- tirzepatide, obstructive sleep apnea, obesity, GLP-1 receptor agonists, GIP receptor agonist, apnea-hypopnea index, weight loss, positive airway pressure, hypoxic burden, sleep disorders, C-reactive protein, systolic blood pressure, cardiovascular risk, anti-obesity drugs, obesity-related sleep apnea, body mass index
- MeSH terms
- Sleep Quality, Glucagon-Like Peptide-1 Receptor Agonists, Tirzepatide, Adult, Hypoxia, Blood Pressure, Body Weight, C-Reactive Protein, Double-Blind Method, Female, Gastric Inhibitory Polypeptide, Humans, Male, Middle Aged, Obesity, Severity of Illness Index, Treatment Outcome, Sleep Apnea, Obstructive, Maximum Tolerated Dose
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.